NASDAQ · BIOX
Bioceres Crop Solutions financials
$0.3455−3.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Jun 30 | Q4 '24 Jun 30 | Q4 '23 Jun 30 | Q4 '22 Jun 30 | Q4 '21 Jun 30 | Q4 '20 Jun 30 | Q4 '19 Jun 30 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — |
| Diluted shares | 63.2M | 63.5M | 63.2M | 42.3M | 39.2M | 36.4M | 30.5M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.7M | $44.5M | $48.1M | $33.5M | $36.0M | $42.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $308.7M | $259.7M | $243.5M | $158.0M | $173.4M | $148.0M |
| Total assets | $763.6M | $852.5M | $818.1M | $518.2M | $394.6M | $297.6M |
| Total liabilities | $468.4M | $501.2M | $487.6M | $359.9M | $304.3M | $236.8M |
| Shareholders' equity | $295.2M | $351.4M | $330.5M | $158.3M | $90.3M | $60.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology